Humira (adalimumab)

Author:

Abbott Laboratories (Chicago, Ill) recently received FDA approval of Humira for reducing the signs and symptoms of active arthritis in patients with psoriatic arthritis. The product is also indicated for reducing the signs and symptoms, including major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderate-to-severe active rheumatoid arthritis. The recommended dosage regimen for Humira for adult patients with rheumatoid arthritis or psoriatic arthritis is 40 mg administered every other week as a subcutaneous injection. The product is supplied in single- use, 1-mL prefilled glass syringes as a sterile, preservative-free solution for subcutaneous administration. For more information, visit www.humira.com.